Published in J Infect Dis on January 01, 1991
Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection. J Clin Microbiol (1993) 1.54
CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun (1993) 1.22
Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin. Infect Immun (1999) 1.19
Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence. Proc Natl Acad Sci U S A (1992) 1.15
Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol (1996) 1.12
Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07
Purification and immunological characterization of a GroEL-like protein from Bordetella pertussis. Infect Immun (1991) 0.95
Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect Immun (2006) 0.90
The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun (1995) 0.89
Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin. Infect Immun (2014) 0.86
Laboratory Diagnosis of Pertussis. Clin Microbiol Rev (2015) 0.81
Comparison of commercially available immunoblot assays measuring IgG and IgA antibodies to Bordetella pertussis antigens. Eur J Clin Microbiol Infect Dis (2011) 0.79
Use of a toxin neutralization assay to characterize the serologic response to adenylate cyclase toxin after infection with Bordetella pertussis. Clin Vaccine Immunol (2016) 0.75
Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun (1983) 8.49
Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics (1981) 7.58
An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med (1998) 6.60
Virulence factors of Bordetella pertussis. Annu Rev Microbiol (1986) 6.41
Nationwide survey of drug-resistant tuberculosis in the United States. JAMA (1994) 6.14
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun (1983) 5.03
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med (1996) 4.86
Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol (1986) 4.48
Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA (1994) 4.44
Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med (1996) 4.27
Molecular characterization of an operon required for pertussis toxin secretion. Proc Natl Acad Sci U S A (1993) 4.12
Morbidity and mortality associated with the July 1980 heat wave in St Louis and Kansas City, Mo. JAMA (1982) 3.69
Extracytoplasmic adenylate cyclase of Bordetella pertussis. Proc Natl Acad Sci U S A (1976) 3.57
Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J Infect Dis (1984) 3.48
Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem (1983) 3.31
Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis (1997) 3.18
Prevalence of HIV infection among intravenous drug users in the United States. JAMA (1989) 3.13
Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J Biol Chem (1983) 3.11
Brief report: congenital tuberculosis. N Engl J Med (1994) 2.95
Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med (1998) 2.92
Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun (1983) 2.85
Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun (1981) 2.77
Risk factors for delayed immunization in a random sample of 1163 children from Oregon and Washington. Pediatrics (1993) 2.74
Adaptation of a conjugal transfer system for the export of pathogenic macromolecules. Trends Microbiol (1996) 2.74
Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun (1988) 2.69
Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med (1999) 2.66
The family of HIV seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States. Public Health Rep (1990) 2.64
Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun (1988) 2.55
Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA (1997) 2.54
Nucleotide sequence and characterization of a repetitive DNA element from the genome of Bordetella pertussis with characteristics of an insertion sequence. J Gen Microbiol (1988) 2.46
Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA (1997) 2.40
ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. J Biol Chem (1984) 2.39
Aerosol infection of mice with Bordetella pertussis. Infect Immun (1980) 2.31
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics (1997) 2.25
Phase-shift markers in Bordetella: alterations in envelope proteins. J Infect Dis (1981) 2.23
Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect Immun (1986) 2.18
Laboratory diagnosis of pertussis: the state of the art. Pediatr Infect Dis J (1987) 2.13
Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol (1985) 2.09
Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis (1999) 2.05
The Vaccine Adverse Event Reporting System (VAERS). Vaccine (1994) 2.02
Comparison of sensitivities to two commercially available tuberculin skin test reagents in persons with recent tuberculosis. Clin Infect Dis (1997) 2.02
Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis (1984) 1.96
The health and economic burden of cigarette smoking in Georgia in 1985. J Med Assoc Ga (1989) 1.94
Sensitivity and specificity of clinical case definitions for pertussis. Am J Public Health (1988) 1.93
Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun (1988) 1.92
Bordetella pertussis adenylate cyclase toxin and hemolytic activities require a second gene, cyaC, for activation. J Bacteriol (1991) 1.90
Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis (2001) 1.90
Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein. J Biol Chem (1988) 1.88
Intracellular localization of the dermonecrotic toxin of Bordetella pertussis. Infect Immun (1979) 1.83
Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis. Science (1994) 1.78
Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77
Completeness and timeliness of tuberculosis case reporting. A multistate study. Am J Prev Med (2001) 1.77
Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J Biol Chem (1983) 1.74
HIV infection among homeless adults and runaway youth, United States, 1989-1992. Field Services Branch. AIDS (1994) 1.71
Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study. JAMA (1994) 1.71
Agglutinating monoclonal antibodies that specifically recognize lipooligosaccharide A of Bordetella pertussis. Infect Immun (1988) 1.71
Immunologic response to early and routine DTP immunization in infants. Pediatrics (1984) 1.71
Binding of pertussis toxin to eucaryotic cells and glycoproteins. Infect Immun (1989) 1.71
Health impact of measles vaccination in the United States. Pediatrics (1985) 1.71
N-Acetyl-D-galactosamine-inhibitable adherence lectin of Entamoeba histolytica. I. Partial purification and relation to amoebic virulence in vitro. J Infect Dis (1985) 1.67
Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. N Engl J Med (1997) 1.67
Pertussis toxin substrate, the putative Ni component of adenylyl cyclases, is an alpha beta heterodimer regulated by guanine nucleotide and magnesium. Proc Natl Acad Sci U S A (1983) 1.67
A train passenger with pulmonary tuberculosis: evidence of limited transmission during travel. Clin Infect Dis (1999) 1.67
Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67
ADP-ribosylation of adenylate cyclase by pertussis toxin. Effects on inhibitory agonist binding. J Biol Chem (1984) 1.67
Transmission of Mycobacterium tuberculosis from medical waste. JAMA (2000) 1.67
Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics (1988) 1.66
Ns and Ni, the stimulatory and inhibitory regulatory components of adenylyl cyclases. Purification of the human erythrocyte proteins without the use of activating regulatory ligands. J Biol Chem (1984) 1.62
Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J (1992) 1.62
Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA (1992) 1.60
HIV seroprevalence surveys in drug treatment centers. Public Health Rep (1990) 1.59
Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory proteins. Nature (1983) 1.59
Toxins of Vibrio cholerae and Escherichia coli stimulate adenyl cyclase in rat fat cells. Nature (1974) 1.58
Nonfermentative bacilli associated with man. I. Nomenclature. Am J Clin Pathol (1970) 1.57
Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med (1992) 1.56
Experimental infection of mongrel dogs with Giardia lamblia cysts and cultured trophozoites. J Infect Dis (1982) 1.56
Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis (1992) 1.55
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am J Epidemiol (1989) 1.53
Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun (1987) 1.52
Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics (1995) 1.52
Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis (1985) 1.51
Identification of Bordetella pertussis infection by shared-primer PCR. J Clin Microbiol (1994) 1.49
Purification and characterization of fimbriae isolated from Bordetella pertussis. Infect Immun (1985) 1.47
The association between occupation and tuberculosis. A population-based survey. Am J Respir Crit Care Med (1996) 1.46
'Normal' CSF in bacterial meningitis. JAMA (1980) 1.46
Pertussis toxin effects on T lymphocytes are mediated through CD3 and not by pertussis toxin catalyzed modification of a G protein. J Immunol (1989) 1.45
Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. J Immunol (1987) 1.45
Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma (1989) 1.43
Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein. Mol Microbiol (1991) 1.42
Pertussis toxin inhibits enkephalin stimulation of GTPase of NG108-15 cells. J Biol Chem (1983) 1.41